IS6861A - Aðferðir og blöndur til að greina efnasambönd sembreyta bólguviðbrögðum - Google Patents

Aðferðir og blöndur til að greina efnasambönd sembreyta bólguviðbrögðum

Info

Publication number
IS6861A
IS6861A IS6861A IS6861A IS6861A IS 6861 A IS6861 A IS 6861A IS 6861 A IS6861 A IS 6861A IS 6861 A IS6861 A IS 6861A IS 6861 A IS6861 A IS 6861A
Authority
IS
Iceland
Prior art keywords
mixtures
detection
methods
inflammatory response
compounds convert
Prior art date
Application number
IS6861A
Other languages
English (en)
Inventor
Pillarisetti Sivaram
Cahoon Shianlen
Saxena Uday
Original Assignee
Reddy Us Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics, Inc. filed Critical Reddy Us Therapeutics, Inc.
Publication of IS6861A publication Critical patent/IS6861A/is

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IS6861A 2000-12-29 2003-06-26 Aðferðir og blöndur til að greina efnasambönd sembreyta bólguviðbrögðum IS6861A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25930600P 2000-12-29 2000-12-29
PCT/US2001/050818 WO2002066978A2 (en) 2000-12-29 2001-12-21 Detection of compounds that modulate inflammatory responses

Publications (1)

Publication Number Publication Date
IS6861A true IS6861A (is) 2003-06-26

Family

ID=22984398

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6861A IS6861A (is) 2000-12-29 2003-06-26 Aðferðir og blöndur til að greina efnasambönd sembreyta bólguviðbrögðum

Country Status (11)

Country Link
US (1) US7273712B2 (is)
EP (1) EP1368648A2 (is)
JP (1) JP2005501222A (is)
BR (1) BR0116606A (is)
CA (1) CA2433348A1 (is)
HU (1) HUP0600450A2 (is)
IL (1) IL156651A0 (is)
IS (1) IS6861A (is)
NO (1) NO20032986L (is)
PL (1) PL366250A1 (is)
WO (1) WO2002066978A2 (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1334207A2 (en) * 2000-10-02 2003-08-13 Reddy US Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
HUP0600450A2 (en) * 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
AU2005271452B2 (en) * 2004-08-03 2011-11-03 Vtv Therapeutics Llc RAGE fusion proteins and methods of use
CN101010430A (zh) * 2004-08-03 2007-08-01 转化技术制药公司 Rage融合蛋白及使用方法
US20060084184A1 (en) * 2004-10-19 2006-04-20 Renovar Incorporated Reagents for urine-based immunological assays
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
EP1971865B1 (en) 2006-01-10 2013-04-17 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
AU2007215503A1 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
WO2007130302A2 (en) 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Rage 융합 단백질
WO2009063307A2 (en) * 2007-11-14 2009-05-22 Bio-Technology General (Israel) Ltd. Inflammatory activity detection method using il-6
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2012113785A1 (en) * 2011-02-21 2012-08-30 Fibrostatin S.L. Methods for treating and diagnosing disease
EP2992333A1 (en) * 2013-05-02 2016-03-09 Stichting Katholieke Universiteit Personalised medicine
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP1334207A2 (en) * 2000-10-02 2003-08-13 Reddy US Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
HUP0600450A2 (en) * 2000-12-29 2006-09-28 Reddy Us Therapeutics Detection of compounds that modulate inflammatory responses
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds

Also Published As

Publication number Publication date
BR0116606A (pt) 2006-05-09
US20020086282A1 (en) 2002-07-04
WO2002066978A3 (en) 2003-01-23
WO2002066978A2 (en) 2002-08-29
IL156651A0 (en) 2004-01-04
PL366250A1 (en) 2005-01-24
NO20032986L (no) 2003-08-13
NO20032986D0 (no) 2003-06-27
JP2005501222A (ja) 2005-01-13
CA2433348A1 (en) 2002-08-29
EP1368648A2 (en) 2003-12-10
US7273712B2 (en) 2007-09-25
HUP0600450A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
IS6861A (is) Aðferðir og blöndur til að greina efnasambönd sembreyta bólguviðbrögðum
NO20023216L (no) Instrumentert sementeringsplugg og system for samme
NO20004554L (no) Sand-detektor
DE60143484D1 (de) Gassensoren
DE60114116D1 (de) Anwesenheitsdetektor
DE60110061D1 (de) Thermoelektrischer entfeuchter
DK1307744T3 (da) Analyseapparat
DE50101406D1 (de) Bildgebender brandmelder
NO20012757L (no) Rörhåndteringsanordning
DK1334182T3 (da) Fremgangsmåde til fremstilling af ikke-bovint chymosin og anvendelse heraf
NO20015672L (no) Plugg til fastgjörelse på hule og på massive bygningsmaterialer
DE60108043D1 (de) Zerstörungsfreies Inspektionsverfahren
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DE60124327D1 (de) Aufzeichnungsgerät
EE200300021A (et) Detektorseade
DE60132196D1 (de) Testsignalisierung
DE60108040D1 (de) Aufzeichnungsgerät
DE60137744D1 (de) Aufzeichnungsgerät
NO20022959L (no) Plugg til fastgjörelse på hule og på massive byggematerialer
DE60115768D1 (de) Gassensor
NO20030822L (no) Nye forbindelser og fremgangsmåter
DK1339723T3 (da) Fremgangsmåde og ester derivater anvendelige til fremstilling af cefalosporiner
DE60136219D1 (de) Fehlstellendetektor
DE60119656D1 (de) Aufzeichnungsgerät
NO20004553D0 (no) Blandinger og fremgangsmÕter for oljefeltanvendelser